pSivida Corp. Reports FDA Labeling Discussions for ILUVIEN® for DME; Advisory Committee Meeting No Longer Necessary

  pSivida Corp. Reports FDA Labeling Discussions for ILUVIEN® for DME;
  Advisory Committee Meeting No Longer Necessary

Business Wire

WATERTOWN, Mass. -- December 18, 2013

pSivida Corp. (NASDAQ: PSDV) (ASX: PVA), a leader in the development of
sustained release, drug delivery products for treating eye diseases, today
announced that its licensee Alimera Sciences has entered into labeling
discussions with the U.S. Food and Drug Administration (FDA) for ILUVIEN® for
Diabetic Macular Edema (DME) and, as a result, reported its agreement with the
FDA that the January 2014 Dermatologic and Ophthalmic Advisory Committee
meeting to discuss ILUVIEN for DME was no longer necessary.

Alimera reported that it plans to respond to the FDA’s October 2013 Complete
Response Letter (CRL) in the first quarter of 2014 and intends to address the
concerns raised regarding the facility at which ILUVIEN for DME is
manufactured and to provide recent safety data from patients in the United
Kingdom and Germany. Alimera reported that the FDA has indicated that new
clinical trials will not be required in connection with the FDA’s review of
ILUVIEN for DME prior to approval.

“We are very pleased with Alimera’s discussion with the FDA with respect to
appropriate labeling for ILUVIEN for DME and next steps required to move it
closer to an FDA approval,” said Paul Ashton, Ph.D., President and CEO of
pSivida. “We look forward to a first quarter resubmission and, hopefully,
approval of this product. If approved, we will be entitled to a $25 million
milestone payment from Alimera and 20% of net profits (as defined) on sales of
ILUVIEN for DME by Alimera in the U.S.”

ILUVIEN is approved and commercially available in the United Kingdom and
Germany and slated to launch in France early next year. ILUVIEN is also
approved in Austria, Portugal and Spain and pending approval in Italy. In
addition, Alimera has filed with the Medicines and Healthcare Products
Regulatory Agency in the United Kingdom as the Reference Member State for ten
additional European Union country approvals through the Mutual Recognition
Procedure. pSivida will be entitled to 20% of net profits (as defined) on
sales of ILUVIEN for DME by Alimera in the EU on a country-by-country basis.

About pSivida Corp.

pSivida Corp., headquartered in Watertown, MA, develops tiny, sustained
release, drug delivery products designed to deliver drugs at a controlled and
steady rate for months or years. pSivida is currently focused on treatment of
chronic diseases of the back of the eye utilizing its core technology systems,
Durasert™ and BioSilicon™, including Tethadur™. pSivida has instituted the
first of two planned pivotal Phase III clinical trials for its lead
development product, Medidur™, an injectable, sustained release micro-insert
for the treatment of posterior uveitis, a chronic back-of-the-eye disease.
ILUVIEN® for the treatment of chronic DME considered insufficiently responsive
to available therapies, which uses the same micro-insert as Medidur and is
licensed to Alimera Sciences, Inc., is marketed in the U.K. and Germany and
has also received marketing authorization in Austria, France, Portugal, and
Spain and is awaiting authorization in Italy. Alimera has filed for ten
additional EU country approvals through the Mutual Recognition Procedure. An
investigator-sponsored clinical trial is ongoing for an injectable,
bioerodible micro-insert to treat glaucoma and ocular hypertension, a product
candidate on which Pfizer Inc. has an option. pSivida's FDA-approved
Retisert®, licensed to Bausch & Lomb Incorporated, provides long-term,
sustained drug delivery to treat posterior uveitis.

1995: Various statements made in this release are forward-looking, and are
inherently subject to risks, uncertainties and potentially inaccurate
assumptions. All statements that address activities, events or developments
that we intend, expect or believe may occur in the future are forward-looking
statements. The following are some of the factors that could cause actual
results to differ materially from the anticipated results or other
expectations expressed, anticipated or implied in our forward-looking
statements: uncertainties with respect to: Alimera's ability to finance,
achieve additional marketing approvals, obtain adequate pricing and
reimbursement for, successfully commercialize and achieve market acceptance
of, and generate revenues to pSivida from, ILUVIEN for DME in the EU;
Alimera's ability to obtain regulatory approval for, and if approved, to
finance, successfully commercialize and achieve market acceptance of, and
generate revenues to pSivida from, ILUVIEN for DME in the U.S.; the ability to
finance, complete and achieve a successful outcome for Phase III trials for,
and file and achieve marketing approvals for, Medidur for posterior uveitis,
including achieving acceptable risk-to-benefit and safety profiles in light of
the CRL for ILUVIEN; initiation, financing and success of Latanoprost Product
Phase II trials and any exercise by Pfizer of its option; ability of Tethadur
to successfully deliver proteins, peptides and other large biologic molecules;
ability to develop product candidates and products and potential related
collaborations; initiation and completion of clinical trials and obtaining
regulatory approval of product candidates; continued sales of Retisert;
adverse side effects; ability to attain profitability; ability to obtain
additional capital; further impairment of intangible assets; fluctuations in
operating results; decline in royalty income; ability to, and to find partners
to, develop and market products; termination of license agreements;
competition and other developments affecting sales of products; market
acceptance; protection of intellectual property and avoiding intellectual
property infringement; retention of key personnel; product liability;
consolidation in the pharmaceutical and biotechnology industries; compliance
with environmental laws; manufacturing risks; risks and costs of international
business operations; credit and financial market conditions; legislative or
regulatory changes; volatility of stock price; possible dilution; absence of
dividends; and other factors described in our filings with the SEC. Given
these uncertainties, readers are cautioned not to place undue reliance on such
forward-looking statements. Should known or unknown risks materialize, or
should underlying assumptions prove inaccurate, actual results could differ
materially from past results and those anticipated, estimated or projected in
the forward-looking statements. Our forward-looking statements speak only as
of the dates on which they are made. We do not undertake any obligation to
publicly update or revise our forward-looking statements even if experience or
future changes makes it clear that any projected results expressed or implied
in such statements will not be realized.

Follow pSivida on social media:





The President's Blog:

For more information on pSivida, visit


In US:
Martin E. Janis & Company, Inc.
Beverly Jedynak, President
+1 312.943.1123; M: +1 773.350.5793
In Australia:
pSivida Corp.
Brian Leedman
Vice President, Investor Relations
+61 (0) 41 228 1780
Press spacebar to pause and continue. Press esc to stop.